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Pneumococcal conjugate vaccine 13 delivered as one primary 
and one booster dose (1 + 1) compared with two primary 
doses and a booster (2 + 1) in UK infants: a multicentre, 
parallel group randomised controlled trial
David Goldblatt*, Jo Southern*, Nick J Andrews, Polly Burbidge, Jo Partington, Lucy Roalfe, Marta Valente Pinto, Vasilli Thalasselis, Emma Plested, 
Hayley Richardson, Matthew D Snape, Elizabeth Miller
Summary
Background Infants in the UK were first offered a pneumococcal conjugate vaccine (PCV7) in 2006, given at 2 and 
4 months of age and a booster dose at 13 months (2 + 1 schedule). A 13-valent vaccine (PCV13) replaced PCV7 in 2010. 
We aimed to compare the post-booster antibody response in UK infants given a reduced priming schedule of PCV13 
(ie, a 1 + 1 schedule) versus the current 2 + 1 schedule and to assess the potential effect on population protection.
Methods In this multicentre, parallel group, randomised controlled trial, we recuited infants due to receive their 
primary immunisations aged up to 13 weeks on first vaccinations by information booklets mailed out via the NHS 
Child Health Information Service and the UK National Health Application and Infrastructure Services. Eligible 
infants were randomly assigned (1:1) to receive PCV13 at 2, 4, and 12 months (2 + 1 schedule) or 3 and 12 months of 
age (1 + 1 schedule) delivered with other routine vaccinations. Randomisation was done by computer-generated 
permuted block randomisation, with a block size of six. Participants and clinical trial staff were not masked to 
treatment allocation. The primary endpoint was serotype-specific immunoglobulin G concentrations values 
(geometric mean concentrations [GMC] in μg/mL) measured in blood samples collected at 13 months of age. Analysis 
was by modified intention to treat with all individuals included by randomised group if they had a laboratory result. 
This trial is registered on the EudraCT clinical trial database, number 2015-000817-32, and ClinicalTrials.gov, number 
NCT02482636.
Findings Between September, 2015, and June, 2016, 376 infants were assessed for eligibility. 81 infants were 
excluded for not meeting the inclusion criteria (n=50) or for other reasons (n=31). 213 eligible infants were 
enrolled and randomly allocated to group 1 (n=106; 2 + 1 schedule) or to group 2 (n=107; 1 + 1 schedule). In group 1, 
91 serum samples were available for analysis 1 month after booster immunisation versus 86 in group 2. At 
month 13, post-booster, GMCs were equivalent between schedules for serotypes 3 (0·61 μg/mL in group 1 
vs 0·62 μg/mL in group 2), 5 (1·74 μg/mL vs  2·11 μg/mL), 7F (3·98 μg/mL vs 3·36 μg/mL), 9V (2·34 μg/mL 
vs 2·50 μg/mL), and 19A (8·38 μg/mL vs 8·83 μg/mL). Infants given the 1 + 1 schedule had significantly 
greater immunogenicity post-booster than those given the 2 + 1 schedule for serotypes 1 (8·92 μg/mL vs 
3·07 μg/mL), 4 (3·43 μg/mL vs 2·55 μg/mL), 14 (16·9 μg/mL vs  10·49 μg/mL), and 19F (14·76 μg/mL 
vs 11·12 μg/mL; adjusted p value range <0·001 to 0·047). The 2 + 1 schedule was superior for serotypes 
6A, 6B, 18C and 23F (adjusted p value range <0·0001 to 0·017). In a predefined numerical subset of all of the 
infants recruited to the study (n=40 [20%]), functional serotype-specific antibody was similar between schedules. 
26 serious adverse events were recorded in 21 (10%) infants across the study period; 18 (n=13) were in the 
2 + 1 group and eight (n=8) in the 1 + 1 group. Only one serious adverse event, a high temperature and refusal to 
feed after the first vaccination visit in a child on the 2+1 schedule was considered related to vaccine.
Interpretation Our findings show that for nine of the 13 serotypes in PCV13, post-booster responses in infants primed 
with a single dose are equivalent or superior to those seen following the standard UK 2 + 1 schedule. Introducing a 
1 + 1 schedule in countries with a mature PCV programme and established herd immunity is likely to maintain 
population control of vaccine-type pneumococcal disease. 
Funding NIHR and the Bill & Melinda Gates Foundation.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
A seven-valent pneumococcal conjugate vaccine (PCV7) 
providing protection against the most common serotypes 
causing pneumococcal disease in children in high-income 
countries was licensed in 2000. The licensing schedule 
consisted of three priming doses at 2, 4, and 6 months of 
Lancet Infect Dis 2017
Published Online 






*Contributed equally to the work
Immunobiology Unit, UCL 
Great Ormond Street Institute 
of Child Health, London, UK 
(P Burbidge BSc, V Thalasselis, 
L Roalfe BSc, H Richardson BSc, 
Prof D Goldblatt MBChB); 
Immunisation Hepatitis and 
Blood Safety Department 
(J Southern PhD, 
Prof E MIller FRCPath), 
Statitstics, Modelling and 
Economics Department 
(N Andrews PhD), Public Health 
England, Colindale, London UK; 
and Oxford Vaccine Group, 
Department of Paediatrics, 
University of Oxford, Oxford, 
UK (J Partington BSc, E Plested, 
M Valente Pinto MD, 
M D Snape MBChB)
Correspondence to: 
Prof David Goldblatt, UCL GOS 
Institute of Child Health, 
London, WC1N 1EH, UK 
d.goldblatt@ucl.ac.uk
Articles
2 www.thelancet.com/infection   Published online November 22, 2017   http://dx.doi.org/10.1016/S1473-3099(17)30654-0
age and a booster dose at 12 to 15 months (3 + 1 schedule). 
In the USA, PCV7 was introduced soon after licensure in a 
3 + 1 schedule and showed both direct and indirect 
protection.1,2 In the UK, PCV7 was introduced with a 
two-dose primary series, at 2 and 4 months of age, 
and a booster dose at 13 months (2 + 1 schedule). 
This introduction followed a pivotal immunogenicity study 
suggesting that 2 + 1 was likely to be effective in the UK 
setting.3 The advantage of reducing the primary schedule 
from three to two doses before the booster included space 
in the infant immunisation for additional vaccines and 
reduced costs. The 2 + 1 schedule proved highly effective at 
reducing pneumococcal disease in immunised children in 
the UK caused by the seven serotypes in the vaccine as well 
as a reduction in invasive pneumococcal disease in the 
unvaccinated population.4 A 2 + 1 PCV schedule is now 
used in 57 countries around the world. In 2010 the UK, 
together with many other countries using PCV7, switched 
from a seven to a 13 valent PCV (PCV13, Prevenar13; 
Pfizer, New York, NY, USA) with a consequent reduction 
in overall vaccine type invasive pneumococcal disease due 
to additional serotypes in PCV13 in vaccine-eligible 
children as well as older unvaccinated age groups.5
With the licensure of meningococcal B vaccine (Bexsero, 
GSK, Rixensart, Belgium) and the decision to introduce it 
into the UK infant immunisation schedule, there has 
been a need to seek ways to reduce the number of doses, 
and overall cost, of vaccines delivered in infancy without 
compromising disease control. One option would be to 
reduce PCV13 to a 1 + 1 schedule, giving one priming dose 
at 3 months of age. Although the immunogenicity of one 
dose in infancy is expected to be lower than two doses, 
findings of a UK study with PCV9 showed higher booster 
responses with fewer priming doses,3 a finding that is well 
documented for meningococcal serogroup C conjugate 
vaccine.6 With the greatly reduced incidence of PCV13 
disease in young children in the UK, and effective herd 
protection, the potentially increased risk of an invasive 
pneumococcal infection between 4 and 12 months of age 
in a child who has only received one dose of PCV13 instead 
of two will be very low. For example, the incidence of 
invasive pneumococcal disease in children younger than 
2 years due to one of the seven serotypes covered by PCV7 
was only 0·38 per 100 000 in 2013/14 epidemiological year5 
compared with a pre-PCV7 incidence of 39·05 per 100 000, 
a 99% reduction. Invasive pneumococcal disease due to 
the additional six serotypes covered by PCV13 achieved an 
89% reduction in incidence in children younger than 
2 years within 4 years of PCV introduction, from 12·67 in 
2008/10 to 1·43 in 2013/14.5 Mathematical models have 
predicted the near elimination of disease due to vaccine 
serotypes within the next few years7 although the 
experience with PCV13 suggests that some serotypes 
might be harder to eliminate.
Recent evidence from Australia suggests that in 
high-income settings, the sustained effect of PCVs is 
driven mostly by the booster dose of PCV provided in the 
second year of life.8 The booster dose contributes to 
the prevention of acquisition of pneumococci in the 
nasopharynx and hence interrupts transmission which 
For more on vaccine 
introduction around the world 
see www.view-hub.org
Research in context
Evidence before this study
Pneumococcal conjugate vaccine (PCV) was originally 
licensed as a 3 + 1 schedule and then as a 3 + 0 schedule 
following pivotal efficacy studies. Immunogenicity studies 
of a 2 + 1 schedule resulted in the use of this schedule in 
national immunisation programmes. Evidence subsequently 
accumulated of the efficacy of a 2 + 1 schedule. To assess 
whether fewer doses of PCV could be used without 
compromising efficacy  we did a systematic literature review 
of 14 databases (Embase, PubMed, Biological Abstracts [BA], 
Pascal Biomed, Global Health, BioAbst/Reports, Reviews, 
Meetings, Cochrane Library, African Index Medicus [AIM], 
Western Region Index Medicus [WPRIM], Index Medicus for 
Eastern Med Region [MEMR], Index Medicus for South-East 
Asia Region [IMSEAR], Latin America and Caribbean Health 
Sciences Info [LILACS], Pan-American Health Organisation 
[PAHO], and IndiaMed [IndMed]), to identify studies that 
assessed alternative reduced pneumococcal vaccine 
schedules, published in English from Jan 1, 2010, 
to Dec 31, 2016, with ad-hoc additions through 
September, 2017. We found no other studies assessing a 
single infant dose of PCV followed by a booster in the 
second year of life.
Added value of this study
This immunogenicity trial, the first of its kind to study responses 
to a booster dose of PCV after just a single priming dose (1 + 1), 
has shown that responses to most serotypes in PCV13 following 
a booster dose at 12 months of age are similar or superior to 
those after a 2 + 1 schedule. This immunogenicity study lays the 
foundation for a move to a reduced dose 1 + 1 schedule in 
countries where a mature PCV programme is in place, coverage 
is high, and vaccine type disease is well controlled.
Implications of all the available evidence
Further studies of 1 + 1 schedules in low and middle income 
countries are currently underway. These, together with invasive 
pneumococcal disease surveillance and carriage studies will 
provide a comprehensive evidence base for future decisions 
about global PCV immunisation strategies. The advantages of 
reducing the number of doses of PCV from three to two in the 
infant immunisation schedule include making space in the 
infant programme for additional vaccines in development and 
potentially reduced costs. PCVs are the most expensive 
vaccines in infant schedules and pressure to reduce costs is 
found universally. Costs saved could be used to purchase other 
lifesaving vaccines.
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impacts on all susceptible individuals including those in 
the first year of life. If one dose of PCV in the first year of 
life adequately primed for a booster response, it might 
be possible to reduce the PCV priming schedule without 
compromising the herd protection afforded by PCV to 
the unvaccinated population.
We designed a trial to compare the response to a 
booster dose of PCV13 when primed with a single PCV13 
dose at 3 months of age compared with the standard UK 
immunisation schedule, where PCV is administered at 
2 and 4 months of age with a booster at 12 months.
Methods
Study design and participants
In this multicentre, parallel group randomised controlled 
clinical trial, we recruited infants aged between 7 and 
12 weeks with no contraindications for  vaccination, as 
defined by Department of Health guidelines. Recruitment 
was  by information booklets mailed out via the NHS 
Child Health Information Service and the UK National 
Health Application and Infrastructure Services, which is 
the agency responsible for the central NHS patient 
database, and via general practices in Gloucestershire 
and Hertfordshire that are part of the National Institute 
for Health Research Network.
Eligible infants had not received any other vaccinations 
(with the exceptions of BCG and hepatitis B). Information 
about the participants’ past medical, medication, and 
vaccination history was collected either by a study 
paediatrician or from the medical records using a 
standardised case report form. Information about maternal 
vaccination during pregnancy with a combined tetanus, 
diphtheria, acellular pertussis, inactivated polio vaccine 
(TdaP/IPV) was based on mothers’ recall. Written informed 
consent was obtained from parents before enrolment. 
Ethical approval was obtained from the Oxfordshire 
Research Ethics Committee (reference number 15/SC/0387).
Randomisation and masking
Infants were randomly assigned (1:1) to receive PCV13 at 
2, 4, and 12 months (2 + 1 schedule) or at 3 and 12 months 
of age (1 + 1 schedule) with block randomisation (block 
size six). Masking was not done for participants and 
clinical trial staff but individuals were allocated to a study 
number with its allocated group sequentially. Samples 
were received in the laboratory coded with no access to 
individual sample identities.
Procedures
The two trial groups differed according to pneumococcal 
conjugate vaccine given. Additionally, all participants 
received routine vaccinations according to the UK schedule: 
combined diphtheria, tetanus, acellular pertussis, 
Haemophilus influenzae type b, and inactivated polio vaccine 
(Infanrix-IPV-Hib, GlaxoSmithKline, Rixensart, Belgium) 
at 2, 3 and 4 months, a meningococcal B vaccine (Bexsero, 
GSK, Rixensart, Belgium) at 2, 4 and 12 months of age, oral 
rotavirus vaccine (Rotarix, GSK, Rixensart, Belgium) at 
2 and 3 months of age, Men C/Hib (Menitorix, GSK, 
Rixensart, Belgium) at 12 months of age, and mumps, 
measles and rubella vaccine at 13 months of age. Participants 
received concomitant paracetamol at 2 and 4 months of age.
Up to 5 mL of whole blood were taken at 5 months 
of age (4 weeks after the second PCV13 dose for one group 
and 8 weeks after the single priming dose for the other) 
and 4 weeks after the 12 month visit. Serological ana-
lysis was done at the WHO reference laboratory for 
pneumococcal serology, Great Ormond Street Institute of 
Child Health, University College London, London, UK. 
Following extraction from whole blood, sera were stored at 
–70°C before assay for serotype-specific immunoglobulin 
G (IgG) to 13 vaccine-type capsular polysaccharides (1, 3, 4, 
5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Sera were 
assayed using the WHO reference ELISA after adsorption 
with cell wall polysaccharide and 22F polysaccharide at a 
concentration of 10 μg/mL as previously described in 
detail.9 This assay is based on the original Wyeth assay 
used to generate the correlate of protection of 0·35 µg/mL. 
The lower limit of assay quantification was 0·15 µg/mL 
and IgG concentrations of 0·35 µg/mL or higher were 
considered protective.10 In a subset of 40 sera functional 
antibodies to 13 serotypes were measured in a multiplexed 
opsonophagocytic assay as previously described.11 Values 
are expressed as an opsonophagocytic assay titre, 
equivalent to the reciprocal of the serum dilution required 
to produce 50% killing of the relevant serotype. Nasal 
swabs were taken at 12 and 18 months of age to assess 
pneumococcal carriage but are not reported here.
Outcomes
The primary endpoint was serotype-specific IgG con-
centrations measured in blood samples collected at 






Group 1 (2 + 1 
schedule; N=106)








Not known 7 3
Age at first PCV dose (days) 60 (55–88) 91 (84–114)
Age at second PCV dose 
(group 1; days)
124 (112–154) ··
Age at booster (days) 371 (359–406) 371 (366–416)
Interval from last primary PCV 
dose to blood sample (days)
30 (21–57) 62 (50–92)
Interval from booster dose to 
blood sample (days)
30 (28–82) 20 (28–64)
Data are n or median (range). PCV=pneumococcal conjugate vaccine.
Table 1: Baseline characteristics of study participants
For the multiplexed 
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13 months of age. Secondary outcomes were serotype-
specific IgG concentrations measured in blood samples 
taken at 5 months of age,  proportions 0·35 µg/mL or 
higher of serotype-specific IgG measured in the blood 
samples taken at 5 and 13 months of age, serotype-
specific functional antibody measured in a subset (20%) 
of blood samples taken at 13 months of age, and  the 
prevalence of carriage of vaccine and non-vaccine 
pneumococcal serotypes at the time of booster and 
6 months later (data not available yet).
 Participants were observed for 15 min after each 
vaccination by a study doctor or nurse, for any immediate 
reactions. Parents completed a diary card for 5 days from 
the day of vaccination and recorded all local and systemic 
adverse events. Unsolicited adverse events and serious 
adverse events occurring between the day of vaccination 
and the subsequent visits were recorded with details 
verified from GP notes as required.
Statistical analysis
The sample size target was 110 per group with an 
anticipated 10% loss to achieve 100 evaluable 
participants per group post booster. Assuming the 
standard deviation of responses post booster was 
0·41 this was sufficient to estimate the ratio of the 
geometric means between the groups with a precision 
of 1·3 times for the 95% confidence interval. It was also 
sufficient to detect 1·5 times differences with more 
than 80% power at a 5% significance level. For 
concentrations and titres, results were log transformed 
and groups 1 and 2 compared by the Kruskal-Wallis test 
for post-primary responses and by normal errors 
regression adjusting for sex and interval to blood 
collection for post-booster responses. The effect of 
maternal immunisation within each group on 
concentrations was also assessed by normal errors 
regression in a post-hoc analysis. Geometric means for 
each group were calculated with 95% confidence 
intervals. Proportions above concentration thresholds 
were compared using Fisher’s exact test and proportions 
calculated within groups with 95% exact confidence 
intervals. Analysis was by modified intention to treat 
with all individuals included by randomised group if 
they had a laboratory result.
This study is registered on the EudraCT clinical trial 
database (2015-000817-32) and ClinicalTrials.gov, number 
NCT02482636.
Role of the funding source
The funders had no role in study design or the collection, 
analysis, interpretation, write up of the data or decision 
to submit the data for publication. The corresponding 
author had full access to all the data in the study and final 
responsibility to submit the data.
Results
Between September, 2015, and June, 2016, 376 infants 
were assessed for eligibility. 81 infants were excluded for 
not meeting the inclusion criteria (n=50) or for other 
reasons (n=31). 213 eligible infants were enrolled and 106 
were randomly allocated to group 1 (2 + 1 schedule) and 
107 to group 2 (1 + 1 schedule). In group 1, 91 serum 
samples were available for analysis following the visit 
1 month after booster immunisation versus 86 in group 2 
(table 1, figure). Median age at recruitment was 
60 and 59 days, respectively for the two groups and the 
median age at the time of the booster was 371 days for 
both groups. The groups were evenly matched in terms of 
age at booster, although the number of infants with a long 
interval to the post-booster blood sample was higher for 
102 serum samples available for analysis 
following visit 1 month after
primary immunisation
86 serum samples available for analysis 
following visit 1 month after
booster immunisation
100 received a booster dose
1 insufficient volume
1 refused sampling
2 failed venepuncture attempts
2 were travelling at the time of
the booster
2 moved from the study area
1 withdrew from the study
1 was lost to follow-up
2 withdrew from the study
1 moved from the study area
1 had vaccine elsewhere
1 sample was insufficient for analysis
1 not received by the laboratory
8 failed venepuncture attempts
97 serum samples available for analysis 
following visit 1 month after
primary immunisation
91 serum samples available for analysis 
following visit 1 month after
booster immunisation
103 received a booster dose
86 completed the study 91 completed the study 
107 allocated to group 2 (1+1)
213 infants randomly allocated 1:1
376 assessed for eligibility
81 excluded
50 not meeting inclusion criteria
31 other
106 allocated to group 1 (2+1)
3 insufficient volume
1 not received by laboratory
5 failed venepuncture attempts
1 vaccinated elsewhere
1 withdrew
1 moved from the study area
2 withdrew from the study
1 sample leaked
9 failed venepuncture attempts
Figure: Consort details
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group 1 (seven vs two >42 days). There was also a chance 
imbalance in sex with 60 boys in group 1 (57%) and 
49 boys in group 2 (46%), with serotype-specific responses 
between 10 and 26% lower in boys post booster. For these 
reasons post booster p values comparing groups are 
presented from the planned analysis in which there was 
adjustment for sex and interval to blood sample.
Table 2 shows the serotype-specific pneumococcal IgG 
values (geometric mean concentrations [GMC] in µg/mL) 
at 5 months of age (1 month post the primary series for 
group 1 and 2 months post the single priming dose for 
group 2), and at 13 months of age, 1 month after the 
booster for both groups. After the booster dose, we 
reported significantly higher GMCs for serotypes 1, 4, 14, 
Post-primary group 1 
(2 m, 4 m; Nmax=97) *
Post-primary group 2 
(3 m; Nmax=102) *
p value† Post-boost group 1 (2 
m, 4 m, 12 m; Nmax=91) *
Post-boost group 2 (3 
m, 12 m; Nmax=86)*




1 1·25 (1·07–1·45) 0·57 (0·47–0·69) <0·0001 3·07 (2·58–3·64) 8·92 (7·42–10·73) 2·73 (2·13–3·51) <0·0001
3 0·28 (0·23–0·33) 0·27 (0·21–0·34) 0·66 0·61 (0·51–0·74) 0·62 (0·52–0·74) 0·93 (0·72–1·19) 0·57
4 1·08 (0·93–1·26) 0·43 (0·36–0·51) <0·0001 2·55 (2·15–3·04) 3·43 (2·86–4·12) 1·29 (1·01–1·64) 0·047
5 0·90 (0·77–1·07) 0·29 (0·24–0·35) <0·0001 1·74 (1·49–2·03) 2·11 (1·81–2·45) 1·15 (0·93–1·42) 0·20
6A 1·25 (1·00–1·56) 0·13 (0·11–0·15) <0·0001 8·62 (7·29–10·21) 6·36 (5·34–7·58) 0·69 (0·54–0·87) 0·002
6B 0·26 (0·20–0·33) 0·09 (0·08–0·09) <0·0001 6·19 (5·10–7·50) 2·39 (1·94–2·94) 0·36 (0·27–0·47) <0·0001
7F 2·46 (2·11–2·88) 0·81 (0·69–0·95) <0·0001 3·98 (3·42–4·62) 3·36 (2·93–3·86) 0·82 (0·67–1·01) 0·059
9V 0·73 (0·60–0·89) 0·18 (0·16–0·21) <0·0001 2·34 (2·00–2·73) 2·50 (2·16–2·88) 1·02 (0·83–1·26) 0·85
14 4·19 (3·23–5·43) 1·13 (0·90–1·40) <0·0001 10·49 (8·84–12·44) 16·9 (13·54–21·08) 1·57 (1·19–2·08) 0·002
18C 0·90 (0·73–1·11) 0·22 (0·19–0·27) <0·0001 1·98 (1·70–2·30) 1·63 (1·42–1·87) 0·78 (0·64–0·95) 0·017
19A 1·56 (1·25–1·96) 0·33 (0·27–0·39) <0·0001 8·38 (7·17–9·80) 8·83 (7·4–10·52) 1·00 (0·79–1·26) 0·98
19F 4·54 (3·80–5·42) 0·64 (0·54–0·76) <0·0001 11·12 (9·46–13·07) 14·76 (12·54–17·37) 1·28 (1·02–1·61) 0·035
23F 0·43 (0·34–0·54) 0·09 (0·08–0·10) <0·0001 2·87 (2·38–3·46) 1·72 (1·44–2·05) 0·56 (0·44–0·73) <0·0001
Data are geometric mean (95% CI). *Table 3 shows actual numbers. †Kruskal-Wallis test. ‡ Adjusted in regression for sex and interval to blood.
Table 2: Post-primary and post-booster serotype specific immunoglobulin G geometric mean concentrations in µg/mL
Post-primary group 1 
(2 m, 4 m; Nmax=97)
Post-primary group 2 
(3 m; Nmax=102)
p value* Post-boost group 1 (2 
m, 4 m, 12 m; Nmax=91)
Post-boost group 2 (3 m, 
12 m; Nmax=86)
p value*





















































































































Data are % (95% CI) [n/N] unless otherwise states. m=month.*Fisher’s exact test.
Table 3: Post-primary and post-booster serotype specific immunoglobulin G concentrations of 0·35 µg/mL or higher
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and 19F in infants who received a single priming dose, 
while for those who received two priming doses booster 
responses to 6A, 6B, 18C and 23F were significantly 
higher. A per-protocol analysis with 24 individuals 
dropped because of the timing of blood sampling or 
vaccination being outside the recommended ranges gave 
similar results. When considered as proportions 0·35 
µg/mL or higher, the accepted correlate of protection for 
PCV responses, we noted no differences post-booster 
between the groups since almost all vaccinees achieved 
this threshold (table 3). When analysing the post-booster 
data using serotype specific correlates previously defined 
by our group,12 comparison between the groups were 
similar to those with 0·35 µg/mL or higher as a cut off. 
Maternal immunisation status had no effect on the post 
booster GMCs in either group. Functional responses as 
measured by opsonophagocytic assay were assessed in a 
subset of 40 vaccinees (19 infants from group 1 and 21 
from group 2) following the booster only. Geometric 
mean titres (GMTs) between the two groups were similar 
(table 4), although the study was not powered on 
functional responses. With the exception of serotype 4, 
for serotypes where IgG was significantly higher in 
group 1 (6A, 6B, 18C, 23F) or group 2 (1, 14, 19F), the 
opsonophagocytic assay GMTs showed the same trend. 
GMCs 2 months after a single dose of PCV13 at 
3 months of age were significantly lower than those 
recorded 1 month after two doses for all serotypes 
except 3 (table 2). When considered as proportions 
0·35 µg/mL or higher a significantly greater proportion 
of children receiving a single priming dose were below 
the correlate of protection post-primary immunisation 
(table 3).  When analysing the data using serotype specific 
correlates previously defined by our group,12 comparison 
between the groups were similar to those with 0·35 µg/mL 
or higher as a cut off. Maternal immunisation status had 
no effect on the post primary GMCs in the 2 + 1 group, 
but, in the 1 + 1 group, post-primary GMCs were lower in 
infants of vaccinated mothers (range 6% lower for 6B to 
62% lower for 14 and significant (5% level) for 1, 3, 4, 5, 14, 
18C, and 19F.
The safety profile for the vaccine was good. 26 serious 
adverse events were recorded in 21 (10%) individuals 
across the study period: 18 (n=13) were in the 2  + 1 group 
and eight (n=8) in the 1 + 1 group. Only one serious 
adverse event, a high temperature and refusal to feed 
after the first vaccination visit in a child on the 2 + 1 
schedule was considered related to vaccine. 
Discussion
This is the first study to formally compare booster 
responses to PCV after one or two priming doses of PCV 
provided to infants in the first year of life. Booster 
responses to five of the 13 serotypes were similar between 
the groups whereas responses to four serotypes were 
better in the single priming dose group compared with 
those receiving PCV according the UK national 
immunisation schedule. Responses to the remaining 
four serotypes, 6A, 6B, 18C and 23F, were lower in the 
1 + 1 group but 1·8 (18C) to 9·2 (6B) times higher than 
the equivalent serotypes specific GMCs measured at 
5 months of age after two priming doses. While a 
correlate of protection after boosting is not defined, a 
correlate of protection for PCV is accepted based on IgG 
concentrations after primary immunisation.10 Analysing 
the proportions higher than this correlate (0·35 µg/mL) 
in both groups after boosting showed that both achieved 
similar proportions higher than 0·35 µg/mL and were 
close to 100% for most serotypes. Enhanced boosting 
after fewer primary doses has been described before for 
meningococcal C conjugate vaccines6 and was shown 
again for some serotypes in this study. The underlying 
mechanism and the reason why this phenomenon only 
affects certain serotypes remains unclear.
As expected, the immunogenicity of a single dose at 
3 months of age was significantly inferior to two doses 
administered at 2 and 4 months of age although it is 
possible that responses would have been slightly higher 
had they been measured at 4 rather than 8 weeks post 
vaccination. Despite low responses to a single dose of 
PCV in infancy, a single dose is associated with significant 
direct protection, though less than with a two or three dose 
priming schedule. In the USA findings of a case-control 
study2 of PCV7 showed efficacy for one dose given to 
infants younger than 7 months of 73% (95% CI 43–87)
whereas in the UK, one dose of PCV13 given to infants 
younger than 12 months for the serotypes in PCV13 but 
not PCV7 had an efficacy of 60% (95% CI 12–82).12 The 
effect of maternal immunisation with a diphtheria toxoid-
containing vaccine significantly reduced the post-primary 
responses to some serotypes in the 1 + 1 group in our 
study so the level of protection after a single dose might 
be less than reported previously in the absence of 
Group 1 
(2 + 1 schedule; N=19)
Group 2 
(1 + 1 schedule; N=21)
1 132 (51–338)* 543 (267–1105)
3 108 (65–180) 144 (106–194)
4 2785 (1439–5392) 2321 (1484–3631)
5 530 (328–857) 667 (393–1130)
6A 6396 (3401–12027) 5294 (3879–7225)
6B 2088 (1224–3560) 1397 (1003–1945)
7F 3344 (2222–5034) 2953 (2353–3705)
9V 2391 (1603–3567) 1842 (1243–2731)*
14 2660 (1685–4201) 3987 (2876–5528)
18C 2783 (1710–4528) 1436 (1044–1975)
19A 3677 (1980–6829) 2915 (1982–4287)
19F 2274 (1425–3630) 2428 (1726–3415)
23F 4053 (2628–6252) 2588 (1789–3744)*
Data are geometric mean (95% CI). *No result for one sample.
Table 4: Post-booster serotype-specific opsonphagocytic 
activitygeometric mean titres in a subset of infants
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maternal immunisation. There was no effect of maternal 
immunisation on post-booster responses in either the 
1 + 1 or 2 + 1 groups.
Establishing an evidence base for reducing PCV doses 
given during primary immunisation from two or three to 
a single dose followed by a booster towards the end of the 
first or in the second year of life, could help countries 
with a mature PCV programme and little vaccine type 
invasive pneumococcal disease to move to a reduced 
dose schedule. A reduction from a total of three to 
two PCV doses would have potentially important 
consequences for both specific countries making the 
change and the global community, by reducing the 
number of vaccines administered at immunisation visits 
and reducing the overall cost of preventing pneumococcal 
disease. Extended PCV vaccines have been licensed on 
immunogenicity alone and thus there is an established 
precedent for using immunogenicity studies to inform 
vaccine policy. An example of this was the evaluation of a 
2 + 1 PCV schedule in the UK infant immunisation 
programme at a time when 3 + 1 was the licensed 
schedule.3 Demonstrating likely efficacy of a 2 + 1 schedule 
followed by implementation and evaluation of the impact 
of such a schedule in the UK has provided additional 
confidence that immunogenicity studies can adequately 
predict performance of PCV vaccines and has led to 
many countries either switching to, or introducing PCV 
in a 2 + 1 schedule.
While it is recognised that a single dose provides less 
protection against disease and carriage than a two-dose or 
three-dose primary series, in high-income countries with 
mature vaccine programmes individual protection is 
rarely required because the probability of exposure to 
vaccine-type infection is low. In England and Wales where 
the incidence of PCV7-type invasive pneumococcal 
disease in children younger than 2 years reduced by 
99% within 8 years of PCV introduction,5 there was near 
elimination of PCV7 serotype carriage both in children 
and in older age groups.13 The resulting herd immunity 
was reflected in an overall reduction (all ages) of 86% in 
invasive pneumococcal disease covered by PCV7 by 
2013/14.5 For the extra six serotypes in PCV13 (ie, those 
unique to PCV13 and not found in PCV7, known as 
PCV13-7) carriage prevalence in individuals younger than 
60 years in England and Wales fell from 18·9% in 2008/09 
to 0·6% by 2012/13, with an associated overall reduction 
in invasive pneumococcal disease covered by the PCV13-7 
serotypes of 69%.13 Serotypes 19A and 3 were the two that 
accounted for the low level of persisting PCV13-7 carriage. 
In the USA, 7–9 years after the introduction of PCV7, 
there was a 97% reduction in the incidence of vaccine-
type invasive pneumococcal disease in children younger 
than 5 years compared with the pre-PCV7 baseline14 while 
there was near elimination of nasopharyngeal carriage 
of PCV7 serotypes amongst healthy children in 
Massachusetts.15 Following PCV13 introduction in 
the USA, PCV13-7 invasive pneumococcal disease 
reduced by 93%16 and carriage of the relevant serotypes 
has reduced amongst children in Massachusets.17
Therefore, the success of a 1 + 1 PCV schedule relies on 
the timely provision of a booster dose and the schedule’s 
ability to sustain indirect protection in a mature PCV 
programme. Toddlers and older children between the age 
of 12 and 36 months of age18 rather than infants19, are 
thought to be the major spreaders of pneumococci to 
their siblings and parents. Vaccinating this age group is 
therefore thought to be critical in establishing and 
sustaining indirect protection, hence reassurance is 
required that the booster response following a single 
priming dose would sustain vaccine efficacy against 
acquisition of carriage.20 As we have shown, for nine of 
the 13 serotypes in PCV, booster responses following a 
single priming dose are equivalent or superior to those 
after two priming doses so no reduction in the prevention 
of vaccine type nasopharyngeal acquisition would be 
anticipated. For the four serotypes where the 1 + 1 schedule 
led to inferior IgG responses, the lowest serotype specific 
correlates of protection (range 0·14–0·20 µg/mL)12 have 
been noted. Whereas at a population level less IgG is 
required to provide protection against infection with 
these serotypes, the association between circulating IgG 
and the prevention of carriage acquisition is unclear. The 
true mechanisms for preventing nasopharyngeal 
acquisition are not known and may be related to the local 
production of IgG by memory B cells resident in the 
nasopharynx rather than circulating IgG.21,22
It is possible that reduced primary responses to a single 
dose allows continued vaccine type carriage in the first 
year of life before boosting. This might be especially 
relevant for those vaccine serotypes that persist, albeit at 
a low level in the community and continue to cause 
disease. A relevant example in the UK setting would be 
serotypes 3 and 19A, which continue to cause cases 
of invasive pneumococcal disease in all age groups. 
For serotype 3, no significant protection has been 
demonstrated in England and Wales with the 
2 + 1 schedule, and invasive pneumococcal disease due to 
this serotype has been increasing since 2013/14.23 For 
19A, for which there has been a major population impact, 
direct protection following a single dose administered 
below the age of 12 months was relatively low (38%, 
95% CI –218 to 89).24 Reduced primary immunity might 
lead to an increase in cases in the first year of life 
although the extent of that increase and whether the 
number of expected additional cases would offset the 
cost savings realised by reducing the number of PCV 
doses administered is not clear.
While we have emphasised the importance of the booster 
dose in sustaining the indirect effect, in most low and 
middle income countries, PCV is administered according 
to the WHO Expanded Programme of Immunisation 
schedule where primary vaccination is scheduled to occur 
at 6, 10, and 14 weeks of age with no later booster dose 
(3 + 0). The long term impact of 3 + 0 schedules is difficult 
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to gauge as few low and middle-income countries have 
established, high quality, population based invasive 
pneumococcal disease surveillance in place and sustained 
high coverage of PCV over a prolonged period of time. In 
The Gambia, where PCV7 was introduced into the routine 
programme in 2009 and replaced in 2011 by PCV13 and 
where vaccine coverage is high, the carriage prevalence of 
PCV7 serotypes appears to be persisting at around 20%.25 
This persistence of carriage is in contrast to the UK and 
the USA where PCV7 carriage has been almost eliminated. 
The epidemiological characteristics of pneumococcal 
carriage and disease in many low-income and middle-
income countries differs from that in high-income 
countries in a number of ways including the relatively high 
carriage frequencies in infants younger than 1 year26 and 
adults.27 It is therefore unclear what the contribution of the 
absence of a booster dose is to the observed persistence of 
PCV7 vaccine type carriage in infants in The Gambia. In 
high income settings it would appear from the experience 
in Australia that a booster dose is integral to optimising the 
long-term impact of PCV.8 However, it would be simplistic 
to compare the impact of PCV in high income countries 
with that seen in low and middle income countries and to 
attribute the difference in vaccine type disease control and 
carriage reduction solely to the presence or absence of a 
booster dose.
The Gavi Alliance currently supplies vaccines and 
vaccine support for the world’s poorest countries and 
projects a spend on pneumococcal vaccines between 
2011 and 2020 of US$4·7 billion (2016 pneumococcal 
AMC annual report28). Most countries receiving Gavi 
Alliance support use a 3 + 0 schedule. An eventual shift to 
a 1 + 1 therefore has very significant financial implications 
with a reduction of approximately one third in vaccine 
costs. This cost reduction is particularly relevant for those 
lower middle income countries who are soon to graduate 
from Gavi Alliance eligibility and will thus be required to 
fund their own PCV programmes. By 2020, 30 of the 
original GAVI Alliance eligible countries will have either 
graduated or be graduating and a potential one third 
reduction in the cost of PCV for such countries could be 
critical for sustaining PCV programmes. Further 
evaluation will be required to establish the relevance of 
our findings to diverse epidemiological settings.
It should be noted that this was an immunogenicity study 
and therefore the translation of immunogenicity findings 
to eventual efficacy when a 1 + 1 schedule is introduced is 
unclear. Furthermore, the study was done in the UK and 
therefore its applicability to low and middle income country 
settings should be interpreted with caution and ideally 
followed up with further immunogenicity studies in 
relevant settings. 
In conclusions, our data suggest that booster responses 
following a 1 + 1 schedule are unlikely to compromise 
long-term control of invasive pneumococcal disease when 
administered in a setting where PCV coverage, particularly 
for the booster dose, is high at local, regional and national 
For more on GAVI 






level, PCV has been used for some years, and pneumo-
coccal disease and carriage of vaccine serotypes has 
already been controlled in all age groups. These conditions 
are currently likely to only be met in high-income 
countries and thus extrapolating this study’s finding to the 
current situation in low and middle-income countries 
should be made with caution. Should a 1 + 1 schedule be 
considered adequate, the ideal conditions and timing 
favouring a switch from the current schedule still need 
consideration. Key to the decision to move to a 
1 + 1 schedule would be acceptance of the role and 
importance of the indirect effect seen with conjugate 
vaccines. The UK Government’s vaccine committee took 
this into account when removing the second dose of 
the three-dose monovalent meningococcal C conjugate 
vaccine schedule from infancy to adolescence, when 
carriage prevalence is likely to be highest.29 Similar 
recognition of the role and importance of the indirect 
effect will be key to underpinning any potential changes to 
the UK PCV infant immunisation programme. A number 
of randomised controlled studies comparing a 1 + 1 PCV 
schedule with existing immunisation schedules in India, 
South Africa, Vietnam, and The Gambia are currently 
underway. These, together with invasive pneumococcal 
disease surveillance and carriage studies will provide a 
comprehensive evidence base for future decisions about 
global PCV immunisation strategies.
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